Evercore ISI lowered the firm’s price target on Stryker (SYK) to $410 from $418 and keeps an Outperform rating on the shares, which were added to the firm’s “Tactical Outperform” list. Q3 results should beat expectations, driven by strong Hips & Knees, while Medical should also be strong, the analyst tells investors in a preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK: